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Proteomics is a new science that focuses on the comprehen-
sive analysis of proteins in intact organisms or in molecule 
machineries, organelles, cells, tissues, or organs. It has become 
an important area of interests in life sciences and has propelled 
the rapid development of cutting-edge biotechnology in the 
21st century. In response to this, the Human Proteome Organi-
zation (HUPO) was launched in 2001. The mission of HUPO is 
to advocate and promote proteomics worldwide and to initiate 
the Human Proteome Project (HPP) to decode the human ge-
nome and to establish the proteomic basis of human physiology 
and pathology. Eleven projects including the Human Liver 
Proteome Project (HLPP) led by China are under way. Gov-
ernments, multinational companies, particularly pharmaceutical 
and analytical instrument companies, as well as the genomic 
company Celera Genomics, have invested heavily, hoping to 
seize the huge potential of proteomics. 
Proteomics was introduced in China in 1997, three years af-
ter the first use of the term. With the logistical support of the 
Chinese central and local governments, China’s National Me-
dium and Long Term Science and Technology Development 
Plan (2006–2020) has made proteome research a core part of 
the first Major Scientific Research Program. The China Human 
Proteome Organization (CNHUPO) was founded in 2003. 
Since its inception, CNHUPO has played an important role in 
encouraging the rapid development of proteomics in China 
through collaboration, training and education by supporting 
scientific projects, annual conferences and international ex-
changes. Excitingly, the Sixth Annual Conference of the 
CNHUPO in 2009 attracted nearly 600 participants, a dramatic 
3-fold increase since the first conference in 2003.   
Proteomics has emerged as a major research area in China 
through the supports of governments and scientists. Many pro-
teome research laboratories, facilities and centers have been 
established in recent years, including the Research Center for 
Proteome Analysis (Key Lab of Proteomics, Institute of Bio-
chemistry and Cell Biology, Shanghai Institutes of Biological 
Sciences, Chinese Academy of Sciences, Shanghai, 200031, 
China), the Institutes of Biomedical Sciences (Fudan Univer-
sity, Shanghai, 200032, China), Proteomics Key Lab (Institute 
of Basic Medicine, Chinese Academy of Medical Sciences), 
and the Beijing Proteome Research Center (BPRC). 
Founded in 2002, the BPRC was the first proteomics insti-
tute established in China. Now it has become a top proteomics 
institute. At the Center, proteomics is used as a means to ex-
ploring and understanding the complex physiological and 
pathological processes taking place in the liver and other or-
gans/tissues/cells. BPRC relocated to the Zhongguancun Life 
Science Park on 29 October 2005 and started its rapid devel-
opment. Now, BPRC is the executive headquarters of HLPP. 
The Ministry of Science and Technology (MOST) of China 
approved BPRC as the core unit of the State Key Laboratory of 
Proteomics (Proteome-SKY) in 2009. 
The BPRC has led multiple national and international pro-
teomics projects. The Chinese Human Liver Proteome Project 
(CNHLPP) is one of them. CNHLPP is an ambitious project 
that aims to construct a human liver proteome reference map 
by cataloguing protein expression, modification and pro-
tein-protein interaction in the liver. The reference map will 
serve as a starting point for the systems biology view of liver 
physiology and pathology and lay the foundation for under-
standing and eventually curing the liver diseases.  
The largest dataset of a human organ proteome, the first 
version of the human liver proteome (HLP), has been estab-
lished by the Chinese Human Liver Proteome Profiling Con-
sortium. This dataset comprises of 6788 proteins each with at 
least two peptides that are identified at 5% false discovery rate. 
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Concurrently, they obtained the human liver transcriptome 
(HLT) dataset using the same sample, which consists of 11205 
transcripts. They found direct association between HLT and 
HLP. Preliminary analysis of HLP revealed that proteins in-
volved in liver-specific functions, such as bile transport, bile 
acid synthesis, and bilirubin metabolism, are well represented 
as expected; proteins involved in metabolism, nutrient transport, 
and blood coagulation, as well as complement systems com-
prise the majority of HLP. MAP kinases and signaling compo-
nents in calcium, adhesion, insulin, and adipocytokine actions 
are identified. Half of the HLP are discovered in liver for the 
first time, and 82.5% of them are of low abundance. For exam-
ple, four members of the cytochrome P450 family and three ion 
channels are described for the first time in liver. The overlap in 
coagulation, anticoagulation, fibrinolysis, and complement 
system between human liver and plasma proteomes is particu-
larly noteworthy, demonstrating a significant positive correla-
tion between the abundance of coagulator proteins in liver and 
plasma. The success of the human liver proteome project will 
have a high impact on the understanding of liver diseases such 
as non-alcoholic steatohepatitis (or NASH), HBV infection, 
and hepatic cancers. The dataset of human liver proteome has 
built a solid foundation for future identification of new bio-
markers and targets of therapeutic intervention in liver dis-
eases. 
The Center has also developed a protein-protein interaction 
map and has comprehensively compared the protein expression 
patterns of human fetal liver samples from different develop-
ment stages with intriguingly different physiological character-
istics. This dataset represents the first comprehensive descrip-
tion of the human liver protein interaction network. They util-
ized the high-throughput yeast two-hybrid technology to map 
the interactions of 5026 human liver proteins. A network of 
3484 interactions amongst 2582 proteins was established and 
72% of them were validated with three independent assays. 
The biological significance of this interaction network has been 
illustrated by the topological analyses of metabolic enzymes, 
liver-specific and liver-disease proteins, as well as their associ-
ated proteins. Of those analyzed, 166 proteins are expected to 
cause a liver phenotype if their function is disrupted and 58 
proteins are potential liver-disease candidates. This dataset will 
help to obtain a system biology outlook of protein interactions 
in human liver cancer cells. Such information will transform 
the field of basic biology research in liver function and impact 
all biological research where protein interactions play a regu-
latory role. 
To facilitate the use of the valuable resources and make 
them accessible to the wider scientific community, we have 
made available publicly databases such as dbLEP (http:// 
dblep.hupo.org.cn), liverbase (http://liverbase.hupo.org.cn) and 
livermap (http://livermap.hupo.org.cn). The Center has accu-
mulated a large volume of primary biological information and 
has begun to appreciate the complexicity of the liver proteome. 
To provide unparalleled capacity for proteomics in the next 
five to ten years, they are building a large national scientific 
facility for proteomics, dubbed Pilot Hub of ENcyclopedical 
proteomIX (PHOENIX). The PHOENIX project is the first 
specialized facility for life sciences of its kind among Chinese 
national large scientific facilities and is headed by BPRC. It 
will host most of the large modern instruments for protein sci-
ence with mass spectrometry, optical molecular imaging, 
cryo-electron microscopy (Cryo-EM), and nuclear magnetic 
resonance (NMR). If such progress continues, it will not be 
long before we find ‘proteomics’ appearing regularly in the 
language of popular science. 
I hope this special issue––At a glance: Proteomics in China 
will stimulate your interest in Chinese proteomics. Enjoy the 
special issue that includes eight papers representing a broader 
overview of proteomics in China.  
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